The optimized anticoagulation strategy in prolonged hemodialysis.

Area of Science:

• Nephrology
• Hematology
• Medical Devices

Background:

• Extended (nocturnal) hemodialysis (ENHD) requires careful anticoagulation management.
• Low-molecular-weight heparin (LMWH) can be administered as a single or divided dose during ENHD.
• Assessing the efficacy of LMWH dosing and the predictive value of anti-Xa levels for dialyzer patency is crucial.

Purpose of the Study:

• To determine if a single injection of LMWH is sufficient to maintain dialyzer fiber patency during ENHD.
• To investigate whether the anti-Xa clotting parameter accurately predicts dialyzer fiber blocking in ENHD.

Main Methods:

• A randomized cross-over study involving 20 stable ENHD patients.
• Comparison of single versus divided LMWH (enoxaparin) injections during midweek ENHD sessions.
• Measurement of plasma anti-Xa activity and assessment of dialyzer fiber patency using micro-computed tomography (µCT).

Main Results:

• No significant difference in the percentage of open dialyzer fibers between single and divided LMWH injection groups.
• Time-averaged anti-Xa activity levels were not significantly different between the two administration methods.
• Anti-Xa activity correlated with LMWH dose but not with dialyzer fiber patency.

Conclusions:

• A single enoxaparin injection is adequate for ENHD sessions up to 8 hours.
• The utility of monitoring anti-Xa levels to predict dialyzer patency requires further investigation.
• Current findings suggest simplified LMWH dosing protocols for ENHD may be feasible.